Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036036 · ClinicalTrials.gov registry record · Phase 2

Study of CP-461 in Patients With Advanced Renal Cell Cancer

A Phase 2 study of Renal Cell Carcinoma, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target
1
Study location

NCT00036036 is a Phase 2 study of Renal Cell Carcinoma that has completed, run by Astellas Pharma. The registered enrollment target is 14 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036036, a Phase 2 study of Renal Cell Carcinoma, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG CP-461

Study Locations (1)

California

  • UCLA Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2001-07
Est. Completion 2003-07
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00036036

The ClinicalTrials.gov registry entry for NCT00036036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CP-461 is the first listed.

NCT00036036 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00036036 about?

NCT00036036 is a clinical study titled "Study of CP-461 in Patients With Advanced Renal Cell Cancer". The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.

What is the current status of trial NCT00036036?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2001-07. Estimated completion is 2003-07.

What conditions does trial NCT00036036 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00036036?

The interventions under investigation include: CP-461 (DRUG).

Who is sponsoring clinical trial NCT00036036?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00036036 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.